Context Therapeutics (CNTX) Profit After Tax (2020 - 2026)

Context Therapeutics has reported Profit After Tax for 7 years, with the latest figure at -$8.7 million in Q1 2026.

• Quarterly Profit After Tax fell 89.65% year-over-year to -$8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$40.2 million (down 45.57% YoY) and the FY2025 annual result came in at -$36.1 million, down 35.17% from the prior year.
• Profit After Tax improved to -$8.7 million in Q1 2026 per CNTX's latest filing, from -$13.0 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$2.3 million in Q2 2024 and troughed at -$17.5 million in Q3 2024.
• A 5-year average of -$6.5 million and a median of -$5.0 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax surged 55.01% in 2024, then plunged 291.55% in 2025.
• Over 5 years, Profit After Tax stood at -$3.6 million in 2022, then plunged by 90.34% to -$6.8 million in 2023, then soared by 50.62% to -$3.3 million in 2024, then tumbled by 289.65% to -$13.0 million in 2025, then surged by 33.36% to -$8.7 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$8.7 million, -$13.0 million, and -$9.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.